# Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue

> **NCT01408953** · PHASE2 · TERMINATED · sponsor: **Tirgan, Michael H., M.D.** · enrollment: 2 (actual)

## Conditions studied

- Keloid

## Interventions

- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT01408953
- **Lead sponsor:** Tirgan, Michael H., M.D.
- **Sponsor class:** INDIV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-02
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Very low accrual rate.
- **Last updated:** 2016-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01408953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01408953, "Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01408953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*